sunitinibnivolumabcabozantinibipilimumab
…een 1L and second-line (2L) therapies) was twice as long versus sunitinib. TFS and survival states for ICI plus vascular endothelial grow…
8articles mentioning drugs
23drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: sunitinib ×
sunitinib
This drug is selected. Its supporting articles are shown below.
Articles mentioning sunitinib
8 articles · page 1 of 1pembrolizumabbortezomibcrizotinibpembrolizumab35sunitinibdasatinib
…umab) are often used in ovarian and cervical cancers. ICIs (eg, pembrolizumab) are effective in mismatch repair-deficient endometrial cancer …
nivolumabsunitinibpembrolizumabaxitinib
…rolled in a first-line phase II trial of the anti-PD-1 antibody nivolumab.13 Together, these data suggest then an immunologically enriche…
valrubicinpembrolizumabnadofaragene firadenovecDurvalumaberdafitinib
…ducted, no agents have received approval, with the exception of valrubicin, largely attributed to factors such as the varied prior BCG exp…
atezolizumabsunitinibdocetaxelavelumabaxitinibrenal cancerlung cancerCURE Lung Cancer
…cancer immunotherapy clinical trials (OAK and POPLAR, comparing atezolizumab to docetaxel in non-small cell lung cancer) as well as a separa…
sunitinibMemorial Sloan Kettering Cancer Centeradvanced renal cell carcinomaimmunotherapyICIs
…mune checkpoint inhibitors (ICIs) and 962 subjects treated with sunitinib. The optimal age to separate young from old was found to be 60.…
enzalutamideapalutamidepazopanibabirateroneolaparibsunitinibcapecitabineimatinibosimertinibabemaciclib+8 more
… 5% had ovarian, renal or lung cancer. The involved drugs were: enzalutamide(25), apalutamide(14), abiraterone (9), abemaciclib(6), capecita…
ipilimumabNivolumabsunitinibnab-paclitaxelAtezolizumabCTLA-4UT Southwestern Medical CenterN Engl J Med
…23–34.Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cel…